Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Correlation Between Rituximab Dose Reduction and Acute Relapses of Neuromyelitis Optica Spectrum Disorder, Lessons From Covid-19 Epidemic Publisher Pubmed



Ashtari F1 ; Mehdipour R2 ; Asgari M3 ; Ghalamkari A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Neurology Department, Isfahan Neuroscience Research Center, Isfahan University of Medical Science, Iran
  2. 2. Isfahan Neuroscience Research Center, Isfahan University of Medical Science, Iran
  3. 3. Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2024


Abstract

Background: COVID-19 was a viral infection that led to a global pandemic in March 2020. At the beginning of the pandemic, clinicians encountered the challenge of how immunosuppressive treatments would affect the course of COVID-19 infection in people with autoimmune diseases. Neuromyelitis optica spectrum disorder is an autoimmune astrocytopathy that is caused by an inflammation in the CNS. Major treatments to prevent acute relapses include immunosuppressive drugs. Rituximab is a well-established immunosuppressive agent in NMOSD maintenance therapy. Some reports suggested that treatment with Rituximab might increase the risk of COVID-19 infection and its mortality in NMOSD. On the other hand, dose reduction or extended interval treatment might lead to acute relapses of NMOSD and permanent disability. Methods: In this study, we evaluated the correlation between the dose of rituximab and the relapse rate of NMOSD during an epidemic. This was an observational study on 171 patients among whom 55 cases were seropositive. Some patients received full dose rituximab routinely (1000 mg/dose, every 6 months), but others were treated with half dose (500 mg/dose) during the epidemic. Also, some doses were prescribed with a delay, based on the level of CD19 and CD20. Results: The Pearson correlation coefficient (r) showed a negative and significant relation (r: - 0.19, p: 0.022) between the amount of drug and the number of relapses in the seropositive group, so low dosage of the drug was related to more acute relapses. In seronegative cases, there was not any valuable relationship. (p: 0.367). Conclusion: Lower dose of rituximab, especially in seropositive NMOSD patients, can potentially lead to acute relapses. So, the more frequent evaluation of the CD19, CD20, and, CD27 levels, and the general clinical condition of the patients should be considered. © 2024 Elsevier B.V.
Experts (# of related papers)
Other Related Docs
11. Diagnosis and Classification of Optic Neuritis, The Lancet Neurology (2022)
12. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
13. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
15. Frequency of Comorbidities in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2021)
18. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders, Neurology: Neuroimmunology and NeuroInflammation (2024)
23. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)